May 30, 2020

May 30, 2020

Subscribe to Latest Legal News and Analysis

May 29, 2020

Subscribe to Latest Legal News and Analysis

May 28, 2020

Subscribe to Latest Legal News and Analysis

FDA 2018 Year in Review: Laboratory-Developed Tests and Precision Medicine

Developments in 2018

In 2018, FDA continued to express its interest in overhauling the regulatory framework applicable to in vitro diagnostic tests, including the laboratory-developed tests (LDTs) for which the agency currently exercises enforcement discretion. Notably, 2018 saw the FDA release long-awaited Technical Assistance on the House Energy and Commerce Committee’s draft Diagnostic Accuracy and Innovation Act. The Technical Assistance reflects several notable changes in the agency’s position—most notably with respect to the agency’s willingness to “grandfather” many currently marketed LDTs into a new diagnostic-specific regulatory scheme (i.e., not to require that such products comply with many of FDA’s regulatory requirements, such as pre-market review). Moreover, FDA indicated its support for the review and approval of prospective protocols, under which test developers and would identify types of changes and procedures for test validation following such changes, and if the agency approved such protocols, developers could make such modifications without a supplemental pre-market filing.

Looking Ahead to 2019

In December 2018, the US House of Representatives Energy and Commerce Committee released an updated draft bill related to in vitro clinical tests (IVCT)—now titled the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018—that is largely consistent with the FDA Technical Assistance. The Energy and Commerce Committee is accepting comments on the draft VALID Act from interested stakeholders until mid-February 2019, and is expected to hold hearings on diagnostic regulatory reform early in 2019. Stakeholders should stay apprised of the status of this bill and other legislative developments, which may have a substantial impact on FDA’s oversight of diagnostics.

Read more on FDA 2018 Year in Review.

© 2020 McDermott Will & Emery


About this Author

Vernessa Pollard Pharmaceutical Attorney McDermott

    Vernessa T. Pollard is a partner in the law firm of McDermott Will & Emery LLP and is based in the Washington, D.C., office. Vernessa serves as co-head of the Firm’s Food and Drug Administration (FDA) practice.

    Vernessa advises companies on regulatory, compliance, enforcement and legislative matters involving pharmaceuticals, medical devices, digital and mobile health, health IT solutions and services, and emerging technologies and software. She also advises national and international food and cosmetic producers and retailers on...

    T Reed Stephens Attorney McDermott Will

    T. Reed Stephens is a partner in the law firm of McDermott Will & Emery LLP and is based in the Firm's Washington, D.C., office.  Reed represents clients involved in the Life Sciences industry, including pharmaceutical and biotech manufacturers, wholesalers, and individuals, as well as health care systems and non-health care related companies in the financial services industry.  In addition to representing clients in matters involving state and federal government law enforcement, voluntary disclosures, and congressional investigations Reed advises clients on mergers...

    202 756 8129
    Michael Ryan Attorney specializing in Pharma law McDermott Law Firm

    Michael W. Ryan is a partner in the law firm of McDermott Will & Emery LLP and is based in the Firm’s Washington, D.C. office.

    Michael focuses his practice on the legal, regulatory and reimbursement issues that manufacturers and investors encounter in the development and commercialization of pharmaceuticals, medical devices, biotechnology products and laboratory services.  Michael counsels entities as they seek to obtain authorization to market their products from the U.S. Food and Drug Administration, maintain compliance with applicable laws and regulations (including the...

    +1 202 756 8088
    Anisa Mohanty, McDermott Law Firm, Health Care Attorney

    Anisa Mohanty advises life sciences companies on regulatory, compliance, enforcement, policy, and legislative matters arising under the Federal Food, Drug, and Cosmetic Act (FDCA). She counsels pharmaceutical, medical device, and consumer product companies on premarket pathways, advertising and promotion, and current Good Manufacturing Practice (cGMP) and Quality System requirements. Anisa also assists clients with US Food and Drug Administration (FDA) engagement strategies and responding to FDA administrative and enforcement actions.